Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation

International Journal of Cancer

Volumn 82, Issue 5, 1999, Pages 721-726

  Chan, Allen K ^a   Lockhart, Diane C ^a   Von Bernstorff, Wolfram ^a   Spanjaard, Remco A ^a   Joo, Hong Gu ^a,b   Eberlein, Timothy J ^a,b   Goedegebuure, Peter S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEMBRANE PROTEIN; MUC 1 MUCIN; UNCLASSIFIED DRUG; CA 15-3 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR WEIGHT; NEOPLASM; PATHOLOGY; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; T LYMPHOCYTE; WESTERN BLOTTING;

ANTIGENS, CD58; BLOTTING, WESTERN; CA-15-3 ANTIGEN; CELL DIVISION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE ACTIVATION; MOLECULAR WEIGHT; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033609726     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19990827)82:5<721::aid-ijc16>3.0.co;2-n     Document Type: Article

References (25)

1. AGRAWAL, B., KRANTZ, M., REDDISH, M., and LONGENECKER, B., Cancer associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature (Med)., 4, 43-49 (1998).
2. BOUSSIOTIS, V.A., FREEMAN, G.J., CRIBBEN, J.G., HAYES, D.F., and NADLER, L.M., No evidence for MUC1-induced apoptosis. Nature. (Med.), 4, 1093, (1998).
3. BURCHELL, J., GENDLER, S., TAYLOR-PAPADIMITRIOU, J., GIRLING, A., LEWIS, A., WILLIS, R., and LAMPORT, D., Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47, 5476-5482 (1987).
4. CIBOROWSKI, P. and FINN, O.J., Recombinant epithelial cell mucin (MUC1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy. Biomed Peptides Proteins mid. Acids, 1, 193-198 (1995).
5. DING, L., LALANI, E.-N., REDDISH, M., KOGANTY, R., WONG, T., SAMUEL, J., YACYSHYN, M.B., MEIKLE, A., FUNG, P.Y.S., TAYLOR-PAPADIMITRIOU, J., and LONGENECKER, B.M., Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother., 36, 9-17 (1993).
6. GIMMI, C.D., MORRISON, B.W., MAINPRICE, B.A., GRIBBEN, J.G., BoussioTIS, V.A., FREEMAN, G.J., PARK, S.Y.L., WATANABE, M., GONG, J., HAYES, D.F., KUFE, D.W., and NADLER, L.M., Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature (Med.), 2, 1367-1370 (1996).
7. GOEDEGEBUURE, P., SPANJAARD, R., and EBERLEIN, T., T cells and tumor-infiltrating lymphocytes. In J.R. Bertino (ed.), Encyclopedia of Cancer III, pp. 1736-1750, Academic Press, Inc., San Diego (1997).
8. HASSAN, H. and WALKER, R., Decreased apoptosis in non-involved tissue from cancer-containing breasts. J. Pathol., 184, 258-264 (1998).
9. HENKART, P., Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity, 1, 343 (1994).
10. LIGTENBERG, M.J.L., BUIJS, F., VOS, H.L. and HILKENS, J., Suppression of cellular aggregation by high levels of episialin. Cancer Res., 52, 2318-2324 (1992).
11. LINEMAN, D., GOEDEGEBUURE, P. and EBERLEIN, T., Vaccine therapy for cancer: A review. Ann. surg. Oncol., 3, 219-228 (1996).
12. LOTZOVA, E., Ovarian tumor-infiltrating lymphocytes: phenotype and anti-tumor activity. Nat. Immunol. Cell Growth Regul., 7, 226-229 (1988).
13. MAKGOBA, M., SANDERS, M., LUCE, G.G., GUGEL, E., DUSTIN, M., SPRINGER, T. and SHAW, S., Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1 dependent adhesion in T cell-mediated cytotoxicity. Europ. J. Immunol., 18, 637-640 (1988).
14. MIESCHER, S., WHITESIDE, T.L., MORETTA, L. and VON FLIEDNER, V., Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol., 138, 4004-4011, (1987).
15. PEOPLES, G., GOEDEGEBUURE, P., ANDREWS, J., SCHOOF, D. and EBERLEIN, T., HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J. Immunol., 151, 5481-5491 (1993).
16. REGIMBALD, L.H., PILARSKI, L.M., LONGENECKER, B.M., REDDISH, M.A., ZIMMERMAN, G. and HUGH, J.C., The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res., 56, 4244-4249 (1996).
17. RESTIFO, N., MARINCOLA, F., KAWAKAMI, Y., TAUBENBERGER, J., YANNELLI, J. and ROSENBERG, S., Loss of functional betal-microglobulin in metatstatic melanomas from five patients receiving immunotherapy. J. nat. Cancer Inst., 88, 100-108 (1996).
18. ROWSE, G.J., TEMPERO, R.M., VAN LITH, M.L., HOLLINGSWORTH, M.A. and GENDLER, S.J., Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res., 58, 315-321 (1998).
19. SAMUEL, J., BUDZYNSKI, W.A., REDDISH, M.A., DING, L., ZIMMERMAN, G.L., KRANTZ, M.J., KOGANTY, R.R. and LONGENECKER, B.M., Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer, 15, 295-302 (1998).
20. SCHOL, D.J.,. MEULENBROEK, M.F., SNUDEWINT, F.G., VON MENSDORFF-POUILLY, S., VERSTRAETEN, R.A., MURAKAMI, F., KENEMANS, P. and HILGERS, J., 'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol., 19(Suppl. 1), 35-45 (1998).
21. TAMIYA, S., ETOH, K., SUZUSHIMA, H., TAKATSUKI, K. and MATSUOKA, M., Mutation of CD95(Fas/Apo-1) gene in adult T-cell leukemia cells. Blood, 91, 3935-3942 (1998).
22. TOPALIAN, S., SOLOMON, D. and ROSENBERG, S., Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol., 142, 3714-3725 (1989).
23. VAN DE WIEL-VAN KEMENADE, E., LIGTENBERG, M.J.L., DE BOER, A.J., BUUS, F., VOS, H.L., MELIEF, C.J.M., HILKENS, J. and FIGDOR, C.G., Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol., 151, 767-776 (1993).
24. WOLTERING, E., W.D., HOLDER, J., EDNEY, J. and SHEPPARD, B. Oncology. In J. O'Leary (ed.), The physiologic basis of surgery (2 ed.), pp. 153-183. Williams and Wilkins, Baltimore (1996).
25. ZHANG, K., SIKUT, R. and HANSSON, G.C., A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell. Immunol., 176, 158-165 (1997).